Cargando…
Acute bilateral myopia induced by Triplixam: a case report
BACKGROUND: Side effects of the systemic drugs used to treat eyes are not common. Triplixam is used to treat systemic hypertension and contains amlodipine, indapamide and perindopril arginine as active ingredients which might have induced the sudden myopia. The transient myopia with objective findin...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510128/ https://www.ncbi.nlm.nih.gov/pubmed/32962672 http://dx.doi.org/10.1186/s12886-020-01635-2 |
_version_ | 1783585725824892928 |
---|---|
author | Jaruseviciene, Ruta Sirvydyte, Ginte |
author_facet | Jaruseviciene, Ruta Sirvydyte, Ginte |
author_sort | Jaruseviciene, Ruta |
collection | PubMed |
description | BACKGROUND: Side effects of the systemic drugs used to treat eyes are not common. Triplixam is used to treat systemic hypertension and contains amlodipine, indapamide and perindopril arginine as active ingredients which might have induced the sudden myopia. The transient myopia with objective findings disappeared after the discontinuation of the drug. CASE PRESENTATION: A 33-year-old male presented to the emergency department with a history of blurred vision in both eyes. Development of myopia, lens thickening, choroidal effusion and retinal striae at the macula with the increase in macular thickness was observed in both eyes. These symptoms cleared completely after the drug was discontinued. Myopisation could have been caused by lens thickening and changing its refractive index as a result of allergic or idiosyncratic reaction of the ciliary body. Retinal striae may be caused by the volume effect of the choroidal effusion. CONCLUSION: Our report describes the adverse effect of Triplixam, probably resulting from its ingredient indapamide. Although indapamide is a common drug used in the treatment of systemic hypertension, it is important for cardiologists, general practitioners and other physicians to be aware of the possible adverse effect of Triplixam. |
format | Online Article Text |
id | pubmed-7510128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75101282020-09-24 Acute bilateral myopia induced by Triplixam: a case report Jaruseviciene, Ruta Sirvydyte, Ginte BMC Ophthalmol Case Report BACKGROUND: Side effects of the systemic drugs used to treat eyes are not common. Triplixam is used to treat systemic hypertension and contains amlodipine, indapamide and perindopril arginine as active ingredients which might have induced the sudden myopia. The transient myopia with objective findings disappeared after the discontinuation of the drug. CASE PRESENTATION: A 33-year-old male presented to the emergency department with a history of blurred vision in both eyes. Development of myopia, lens thickening, choroidal effusion and retinal striae at the macula with the increase in macular thickness was observed in both eyes. These symptoms cleared completely after the drug was discontinued. Myopisation could have been caused by lens thickening and changing its refractive index as a result of allergic or idiosyncratic reaction of the ciliary body. Retinal striae may be caused by the volume effect of the choroidal effusion. CONCLUSION: Our report describes the adverse effect of Triplixam, probably resulting from its ingredient indapamide. Although indapamide is a common drug used in the treatment of systemic hypertension, it is important for cardiologists, general practitioners and other physicians to be aware of the possible adverse effect of Triplixam. BioMed Central 2020-09-22 /pmc/articles/PMC7510128/ /pubmed/32962672 http://dx.doi.org/10.1186/s12886-020-01635-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Jaruseviciene, Ruta Sirvydyte, Ginte Acute bilateral myopia induced by Triplixam: a case report |
title | Acute bilateral myopia induced by Triplixam: a case report |
title_full | Acute bilateral myopia induced by Triplixam: a case report |
title_fullStr | Acute bilateral myopia induced by Triplixam: a case report |
title_full_unstemmed | Acute bilateral myopia induced by Triplixam: a case report |
title_short | Acute bilateral myopia induced by Triplixam: a case report |
title_sort | acute bilateral myopia induced by triplixam: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510128/ https://www.ncbi.nlm.nih.gov/pubmed/32962672 http://dx.doi.org/10.1186/s12886-020-01635-2 |
work_keys_str_mv | AT jarusevicieneruta acutebilateralmyopiainducedbytriplixamacasereport AT sirvydyteginte acutebilateralmyopiainducedbytriplixamacasereport |